Lilly Ventures Fund I LLC

CIK 1575852 · last filed 2018-04-23

Lilly Ventures Fund I LLC is a corporate insider who has filed 6 SEC Form 4 insider transactions across 6 companies since 2013. The most recent filing, for SURF, was dated Apr 23, 2018. Across all open-market trades the lifetime net is +$65.4M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $300.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$300.10M

Companies

6

Total Filings

6

Lifetime Open-Market Net

$65.41M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Surface Oncology, Inc. (SURF) Delisted	10%+ Owner	3,181,817	$1.07	$3.40M	$15.96M	1	2018-04-23
Rein Therapeutics, Inc. (ALRN) Delisted		42,249	$2.11	$89.1K	$15.00M	1	2017-07-07
PTGX	10%+ Owner	2,099,482	$140.91	$295.84M	$28.00M	1	2016-08-16
Spyre Therapeutics, Inc. (AGLE) Delisted	10%+ Owner	2,068,543	$12.01	$24.84M	$0	1	2016-04-14
CHRS		3,042,019	$1.40	$4.26M	$4.45M	1	2014-11-12
Receptos, Inc. (RCPT) Delisted	10%+ Owner	1,938,353	—	—	$2.00M	1	2013-05-14

Recent Filings

6 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2018-04-23	Surface Oncology, Inc. (SURF) Delisted	Mixed	+13,791,268	$15.96M	EDGAR
2017-07-07	Rein Therapeutics, Inc. (ALRN) Delisted	Mixed	+4,379,948	$15.00M	EDGAR
2016-08-16	PTGX	Mixed	+8,397,928	$28.00M	EDGAR
2016-04-14	Spyre Therapeutics, Inc. (AGLE) Delisted	Conv (C)	+6,032,772	$0	EDGAR
2014-11-12	CHRS	Mixed	+6,084,038	$4.45M	EDGAR
2013-05-14	Receptos, Inc. (RCPT) Delisted	Mixed	+1,966,925	$13.24M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.